Market Overview

Here's Your March PDUFA Date Preview

Here's Your March PDUFA Date Preview

The PDUFA dates are a key catalyst for any pharma company, especially biotechs, as this is the date when the FDA gives its verdict on the drug’s NDA. The Prescription Drug User Fee Act typically calls for a period of 10 months to review such applications.

March is a month Merck & Co., Inc.(NYSE: MRK) investors were keenly focusing as the company faces key PDUFA catalysts.

Merck’s Keytruda has a PDUFA priority review date on March 8 for Microsatellite Instability-High Cancer and the same drug will have a PDUFA review date on March 15 for Relapsed or Refractory Classical Hodgkin Lymphoma.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is having a PDUFA review date on March 29 for Dupixent (dupilumab) for the treatment of Atopic dermatitis.

In addition, Radius Health Inc (NASDAQ: RDUS)’s PDUFA date for Abaloparatide-SC to treat Osteoporosis is on March 30.

Related Link: 5 Attractive Stocks Trading At A Reasonable Price

Related Link: 10 Stocks To Watch For March 8, 2017


Related Articles (MRK + RDUS)

View Comments and Join the Discussion!

Posted-In: Biotech News Previews FDA Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at